Medical News

When a trained patient navigator called eligible current and former smokers and directly scheduled their LDCT, 32% completed screening at 12 months — versus 11% with a reminder letter and 5% with usual care. For a panel of 500 eligible patients, this means roughly 135 additional screened patients and proportionally more early-stage cancers caught annually.

The first randomized trial to target nonobstructive HCM directly: aficamten (cardiac myosin inhibitor) produces a +0.67 mL/kg/min improvement in peak VO₂ and +3.0-point KCCQ-CSS improvement over placebo in 517 patients across 8 countries. This completes the picture — aficamten now shows benefit in both obstructive and nonobstructive HCM.

Closed-loop autonomous oxygen delivery significantly increases time within a defined normoxemia window (SpO2 92–96%) on medical wards versus conventional nurse-adjusted titration. This trial quantifies how much hyperoxia patients accumulate between nursing checks — and proves the hardware exists to eliminate it.

Immunogenicity trials show comparable or superior HAI titers versus standard egg-based flu vaccine, no egg-adaptation mutations, and a programmability advantage for rapid strain updates. The approval extends the COVID-19 mRNA platform into seasonal flu and eliminates the egg-allergy contraindication question entirely.

Pfizer's brepocitinib (TYK2/JAK1 dual inhibitor) receives FDA approval for adult dermatomyositis after meeting its primary TIS endpoint and all 9 secondary endpoints in the VALOR trial — the first oral therapy approved for an inflammatory myopathy. The mechanism targets type I interferon signaling directly, addressing the core immunopathology of dermatomyositis.

A JAMA randomized trial shows 5-fraction SBRT is non-inferior to 20–28 fraction IMRT for both disease-free survival and patient-reported urinary and bowel quality of life at 2 years. For intermediate-risk prostate cancer, SBRT is now a supported standard: same cancer control, same quality of life, dramatically fewer clinic visits.

Takeda's rusfertide becomes the first synthetic hepcidin mimetic approved by any regulatory agency, targeting the iron-sensing pathway rather than the JAK2 mutation itself. The VERIFY trial (N=293) showed 76.9% clinical response versus 32.9% placebo, phlebotomy requirements dropped from 1.8 to 0.5 per 12 weeks, and HCT <45% was sustained in 62.6% vs 14.4%.

The Phase 3 FIND-CKD trial demonstrates that finerenone — the nonsteroidal MRA proven in diabetic CKD — significantly slows eGFR decline and reduces cardiovascular-kidney composite events in non-diabetic CKD patients already on maximal RAS inhibition. Aldosterone-driven fibrosis operates in CKD regardless of diabetes etiology.

Zabopegdutide targets glucagon receptors alongside GLP-1 and GIP, driving hepatic fat oxidation directly. Phase 2 trial in biopsy-confirmed MASH (F2–F3) shows 62.5% histologic MASH resolution with no worsening of fibrosis at 48 weeks, along with 14% mean weight reduction and 45% fibrosis stage improvement.

Two parallel Phase 3 replicate RCTs show upadacitinib 30mg achieves SALT ≤20 (80% scalp coverage) in approximately 35–40% of patients with severe AA versus 5–8% on placebo. Adolescents respond comparably to adults. The JAK inhibitor revolution in alopecia areata now has three FDA-approved agents — baricitinib, ritlecitinib, and now upadacitinib pending approval.

VALOR trial OLE data show patients who received tofersen continuously from baseline maintained better ALSFRS-R trajectories than delayed-starters at every timepoint through 2+ years. Motor neuron loss during the placebo period is irreversible — the window for maximum benefit is before substantial functional impairment. SOD1 testing in new ALS patients is now standard of care.

A meta-analysis of 15 RCTs with 2,847 participants confirms CGM reduces A1c by approximately 0.5% in non-insulin type 2 diabetes. The benefit is largest in those with A1c ≥8.5%, attenuates beyond 6 months, and works through behavior change — not insulin titration. This review quantifies who benefits most and where the evidence gaps remain.

Lung ultrasound-guided management of chronic heart failure allows individualized diuretic adjustment based on B-line counts at outpatient visits — reducing urgent hospitalizations and emergency visits at 6 months compared to standard care. This is the first RCT to show a major clinical endpoint benefit from outpatient LUS monitoring in HF.